Rising oil prices could lift manufacturing costs of an HIV drug, Unitaid report says

Rising oil prices, driven in part by geopolitical tensions, have raised concerns about the stability of medicine supply chains. Analysts note that higher energy costs can translate into increased production expenses for pharmaceuticals that rely on petrochemical inputs.

A new Unitaid analysis focused on a widely used HIV medication and estimated that if oil prices reach $120 per barrel, manufacturing costs could rise by about 15 percent. The report attributes roughly 85 percent of that increase to the cost of petrochemical ingredients used in the drug's production.

Julien Pouille, who leads Unitaid's climate and health strategic team, argues that reducing dependence on fossil‑based raw materials would help shield drug costs from oil price volatility while also delivering climate benefits.

The findings highlight a broader risk for the pharma sector: as energy markets fluctuate, companies may need to explore alternative sourcing or reformulation strategies to maintain price stability and ensure patient access.